MARKET

SRNE

SRNE

Sorrento Thera
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.480
+0.460
+22.77%
After Hours: 2.380 -0.1 -4.03% 19:27 04/03 EDT
OPEN
1.970
PREV CLOSE
2.020
HIGH
2.680
LOW
1.970
VOLUME
27.88M
TURNOVER
--
52 WEEK HIGH
5.09
52 WEEK LOW
1.390
MARKET CAP
449.72M
P/E (TTM)
-1.1051
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average SRNE stock price target is 22.50 with a high estimate of 24.00 and a low estimate of 21.00.

EPS

SRNE News

More
  • NRZ, TWO, SRNE and CNX among midday movers
  • Seeking Alpha - Article · 1d ago
  • SORRENTO TO PROVIDE MANUFACTURING SUPPORT TO CELULARITY AS CYNK-001 NK CELL TRIAL FOR COVID-19 BEGINS ENROLLING PATIENTS
  • GlobeNewswire · 2d ago
  • Analyst Impressed by Sorrentos COVID-19 Pipeline, Says Buy
  • TipRanks · 3d ago
  • Sorrento to test COVID-19 candidates in infection cell model with live virus
  • seekingalpha · 3d ago

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About SRNE

Sorrento Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, acquisition, development and commercialization of drug therapeutics. Its primary therapeutic focus is oncology, including the treatment of chronic cancer pain. It is also developing therapeutic products for other indications, including immunology and infectious diseases. Its products in the pipeline include Chimeric Antigen Receptor-T Cell (CAR-T) programs, resiniferatoxin (RTX), and biosimilar/biobetter antibodies clinical development programs. Its pipeline also includes preclinical fully human therapeutic monoclonal antibodies (mAbs), including biosimilars/biobetters, fully human anti-PD-L1 and anti-PD-1 checkpoint inhibitors derived from its G-MAB library platform, antibody drug conjugates (ADCs), bispecific antibodies (BsAbs), as well as CAR-T and Chimeric Antigen Receptor Natural Killer (NK) cells (CAR. NK) for adoptive cellular immunotherapy.
More

Webull offers kinds of Sorrento Therapeutics Inc stock information, including NASDAQ:SRNE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SRNE stock news, and many more online research tools to help you make informed decisions.